Drugs / AZD2389
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07069725 | May 2025 → Jul 2026 overdue | cirrhosis of liver, fibrotic liver disease | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06974565 | May → Jul 2025 | liver disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06973005 | May → Jul 2025 | liver disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06846528 | Feb → Apr 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06812780 | Feb → Sep 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06138795 | Nov 2023 → Aug 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07610837 | May 2026 → Jul 2027 expected | cirrhosis of liver, fibrotic liver disease | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT06750276 | Dec 2024 → Jul 2025 | cirrhosis of liver, fibrotic liver disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2389 | “Drug: AZD2389” NCT06973005 ↗ |
| Action | Inhibit | “inhibitor of FAP” NCT07610837 ↗ |
| Modality | Small molecule | “small molecule” NCT07610837 ↗ |
| Route | Oral | “Participants will receive AZD2389 orally as a single ascending dose or multiple ascending dose.” NCT06138795 ↗ |
| Target | FAP | “inhibitor of FAP” NCT07610837 ↗ |